Probiotic Fruit Pie New; Herbalife lowered net sales forecast | the 39th week of 2021

Baby and children's food brand good little brute on the new probiotic fruit pie

Recently, the baby food brand is a new baby probiotic fruit pie, each containing 35% selected fresh fruit to maintain a rich flesh taste, but also specially added Lactobacillus acidophilus, Lactobacillus casei two kinds of probiotics to protect the baby's gastrointestinal health; in terms of eating experience, the product taste Q elastic tender, effectively avoid baby choking; in addition, the product does not add carrageenan, flavor, artificial pigments, etc., to help the baby thrive, the existing strawberry, kiwi fruit two flavors, Tmall flagship store price of 100g / box / 25.8 yuan.

Health snack brand ffit8 completed a round of financing of 10 million yuan A+

Recently, health snack brand ffit8 completed tens of millions of yuan A+ round of financing, led by BAI Capital, fosun Ruizheng Capital and Houwei Capital (Mango Dimension Fund) followed. This round of financing will be mainly used for category expansion and supply chain construction. It is understood that this is the third financing completed by ffit8 in one year.

Danone invested 16.5 million euros in a new plant beverage production line

Recently, in order to meet the strong demand for plant-based products from French consumers, Danone injected 16.5 million euros into the Alpro plant-based beverage plant in Isenheim, Haute-Rhine, France, to add a new production line, bringing the total number of production lines to six. The new line will be operational in July 2022.

Herbalife: Adjusted sales forecasts for the third quarter and full year of 2021

Recently, Herbalife lowered its net sales forecast for the third quarter and full year of 2021 after experiencing lower-than-expected distributor promotions. The net sales growth rate in the third quarter is currently expected to remain between 14-18% year-on-year; the full-year net sales growth rate will be between 4.5% and 8.5%. Compared to previous full-year 2021 estimates, this adjustment reflects a 400 basis point reduction in the midpoint.

Pet nutrition brand Solid Gold Surigo released its latest scientific research results

On September 15, Solid Gold, an imported pet nutrition brand under Jianhe Group that focuses on intestinal health, released the latest scientific research results, "After feeding comparison tests, the results show that Solid Gold Sulligao cat and dog staple food products have obvious effects in improving the quality of pet feces and promoting hair growth." ”

Health product company Thorne Healthtech intends to list on the NASDAQ

On September 21, the company Thorne Healthtech (stock code: "THRN") updated its prospectus to the US SEC and announced that the issuance range is $13 to $15, and it intends to list on the NASDAQ in the near future. Thorne Healthtech issued 9 million shares, raising up to $135 million. In terms of issuance intervals, Thorne Healthtech is valued at about $900 million.

Founded in 1984, Thorne Healthtech is a science-oriented health company that provides personalized dietary supplements, nutraceuticals, and health supplements with a customer base of over 3 million.

Juhao Mall H1 has a total revenue of 68.1 million US dollars

On September 22, JWEL. US) announced its results for the first half of 2021. In the first half of this year, the total revenue of Juhao Mall reached 68.1 million US dollars, an increase of 152.6% from 27 million US dollars in the first half of 2020. Among them, the growth rate of cosmetics and health nutrition supplements continued to lead, and the performance of the segment increased by 272.0% and 140.1% respectively. Juhao Mall is a proprietary specialty e-commerce platform under Longrich, with main products including cosmetics, health and nutrition products and household daily necessities.

For the first time, Jingdong disclosed that maternity products have become a new outlet: the sales growth rate of domestic products has exceeded that of imported goods by more than twice

The "2021 Jingdong Maternal Nursing Trend Insight White Paper" (hereinafter referred to as the "White Paper") released by Jingdong Supermarket recently shows that skin care, makeup, oral and home physiotherapy have become the seven new trends in maternal consumption.

The "White Paper" shows that compared with maternal and infant consumption, including maternal care, pregnant mother clothing, pregnancy personal care / skin care / makeup and other categories of consumption, the proportion of pregnant families in the consumption has reached 49%, "pregnant women / lactation" has become a high-frequency search term for pregnant mother care consumers, pregnant mother care market as a whole shows a broad space for growth. In terms of sales, the sales growth rate of domestic brands in many categories such as maternal personal care, maternal skin care and maternal makeup has reached more than 2 times that of imported brands.

Adjuvant treatment of infertility is included in medical insurance The National Medical Insurance Bureau replied

A few days ago, the National Medical Security Bureau released the "Reply to Recommendation No. 5581 of the Fourth Session of the Thirteenth National People's Congress" on its official website. In response to the "Proposal on the Inclusion of Infertility Assisted Treatment in National Medical Insurance to Increase Population Growth" put forward by the Deputies to the National People's Congress, the National Medical Security Bureau replied that in order to promote the long-term balanced development of the population, the medical insurance department has included ovulation-promoting drugs such as bromocriptine, trippreeline, and clomiphene into the scope of payment, improving the level of medication protection for infertility patients.

At the same time, in terms of diagnosis and treatment projects, we will guide all localities, based on the positioning of "guaranteeing the basics", on the basis of scientific calculation and full demonstration, and gradually incorporate the therapeutic assisted reproductive technology that medical insurance can afford into the scope of medical insurance payment according to procedures.